A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant Pt(IV) Prodrug Activation

Citation for published version:

Digital Object Identifier (DOI):
10.1002/anie.201908511

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Angewandte Chemie International Edition

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
COMMUNICATION

A Dual Killing Strategy — Photocatalytic Generation of Singlet Oxygen with Concomitant Pt(IV) Prodrug Activation

Daniel Norman,[a] Alessia Gambardella[a], Andrew Mount[a], Alan Murray[b] and Mark Bradley*[a]

Abstract: A Ruthenium-based mitochondrial-targeting photocatalyst that undergoes efficient cell uptake, enables the rapid catalytic conversion of Pt(IV) prodrugs into their active Pt(II) counterparts and drives the generation of singlet oxygen was designed. This duality drives two orthogonal killing mechanisms with cytotoxicity mediated with temporal and spatial control and was shown to elicit cell death of a panel of cancer cell lines including those showing oxaliplatin-resistance.

Photodynamic therapy (PDT) utilizes photosensitisers (PS) in combination with illumination to generate cytotoxic reactive oxygen species (ROS); primarily singlet oxygen ($^{1}$O$_{2}$).[1] As this only occurs in areas where light is focused, it enables spatially selective cytotoxic effects. Clinical applications of PDT include skin tumours[2] and head and neck cancers[3] as these are optically readily accessible.

Several porphyrin-based photosensitisers have been approved for clinical use including photofrin,[4] however it has serious side-effects in that patients may exhibit severe photosensitivity,[5] as well as non-specific damage to surrounding healthy tissue.[6] Recently, a ruthenium-based photosensitiser, TLD-1433, completed Phase I/II clinical studies for bladder cancer treatment. This trial demonstrated the safety of this PS and also the utility of PDT at wavelengths outside of the “optimal window” with cancers that may not be considered optically accessible.[7]

A related therapeutic concept involves photo-activatable produgs, whereby irradiation generates a cytotoxic drug from an inert prodrug.[8]. Of relevance are the Pt-based photo-activatable produgs developed by Sadler et al[9] where irradiation of a diazido-Pt(IV) complex gives rise to the cytotoxic Pt(II) counterpart, eliciting a dramatic increase in cytotoxic effect, ideal for photo-activated chemotherapy applications. Riboflavin has also been shown to be an effective photocatalyst for the conversion of Pt(IV) complexes to their cytotoxic Pt(II) counterparts[10] (for other Pt(IV) approaches see review by Lippard et al[11]).

Herein, we report the design, synthesis and evaluation of a photocatalytic Pt(IV) prodrug activation platform capable of reducing Pt(IV) produgs while simultaneously generating singlet oxygen (Scheme 1). The Pt(IV) produgs were designed to be “bio-inert” prior to photochemically-induced reduction, while the photosensitiser (PS-1) was shown to be taken up rapidly by cells and localized in the mitochondria. Upon irradiation at 470 nm, the photosensitisers were capable of activating Pt(IV) produgs, while also causing significant oxidative damage to cells, thus affording a spatially- and temporally-controlled cytotoxic effect. The ability of this Pt(IV) prodg activation system to overcome drug resistance was explored. While the commercial photosensitiser, Ru(bpy)$_3$Cl$_2$, was found to be capable of reducing Pt(IV) species, it had limited cell uptake. Therefore, a derivative, PS-1, was synthesized by addition of 1,3,3-trimethyl-2-methyleneindoline to 4-formylphenyl boronic acid (Scheme 2), followed by Suzuki-Miyaura coupling with 4-bromo-2,2’-bipyridine to afford the desired ligand that was treated with Ru(bpy)$_3$Cl$_2$ with replacement of the chloro ligands driven by microwave heating.

Scheme 1. Representation of the photocatalytic conversion of Pt(IV) produgs to their active Pt(II) counterparts by a Ru(II) photocatalyst with simultaneous $^{1}$O$_{2}$ generation.

Ruthenium-based photosensitisers generally display characteristic light absorption profiles[12] due to ligand-to-ligand ($\pi$-$\pi^*$) and metal-to-ligand ($d\text{-}$$\pi^*$) charge transfer bands and these were observed for PS-1 (Figure S1). The singlet oxygen quantum yield of PS-1 was quantified by the Singlet Oxygen Sensor Green (SOSG) assay[13] and found to be 0.72 (comparred to 0.88 for Ru(bpy)$_3$Cl$_2$[14]) (Figure S2). In the presence of a Pt(IV) complex (Pt-c), the quantum yield reduced to 0.37. The photo-activation of the Pt(IV) species was desired to occur intracellularly so cellular uptake of PS-1 was determined by ICP-MS. PS-1 was observed to be taken up well by all three cell lines used, with 62-90% of the compound added to the culture media taken up into the cells after 4 h (see Table 1). The high cellular uptake of PS-1 attributed to the positively charged indoline moiety and the lipophilic nature of the ligands, facilitating passage across the...
negatively charged cell membrane; a feature that can be accentuated in cancer cells. The stability of PS-1 in complex media was demonstrated by incubation in 10% FBS in DMEM (Figure S3).

The ability of PS-1 to elicit cell death upon illumination of light was confirmed in SKOV-3-wt cells (Figure S4). In the dark, PS-1 has negligible effects on cell viability whereas when illuminated it generates cytotoxic reactive oxygen species (IC_{50} = 17 µM). To identify a "bio-inert" Pt(IV) prodrug, a series of symmetrical and non-symmetrical Pt(IV) complexes, Pt-a to Pt-g, were synthesized using standard conditions and screened against biological reductants to identify Pt(IV) prodrugs that were resistant to the biological reductants glutathione (GSH) and ascorbic acid (AsA) (Figure S5).

The non-symmetrical Pt(IV) complexes carrying an axial acetate ligand and either tert-butoxide or benzoate axial ligands (Pt-c and Pt-d) were stable to reduction by glutathione or ascorbic acid. Symmetrical complexes with increased steric hindrance, (Pt-f and Pt-g) were ineffective at preventing reduction. Electron-withdrawing axial ligands, such as trifluoroacetate (Pt-b and Pt-e) were unstable towards biological reductants, presumably due to destabilisation of the Pt(IV) center as has been observed previously. Pt-e has also previously been shown to hydrolize in solution to Pt-b expediting further reduction. Prior work correlating trends of physicochemical properties of Pt(IV), such as reduction potential or logP have shown possible links to biological stability or activity. Analyses of the reduction potentials of Pt-a to Pt-g, showed that Pt-c had the highest reduction potential (0.86 V), which may confer its stability towards biological reductants (Figure S6 and Table S5). However, this is not the only determinant factor as similar reduction potentials were observed for Pt-f and Pt-g (~0.86 V and ~0.74 V, respectively), which were not stable towards biological reductants. The complex Pt-d exhibited low water solubility and was discontinued from further studies with Pt-c taken forwards. Pt-c was also found to be relatively stable in 10% FBS in DMEM, as measured by HPLC (Figure S7). The difference in cytotoxicity of Pt-c compared to the clinical drug, oxaliplatin (OxPt), was analysed in HCT116 and SKOV-3-wt cells, showing that Pt-c exhibited significantly reduced cytotoxicity compared to the parent drug with IC_{50} of 64 vs 9 µM for SKOV-3-wt and 97 vs 6 µM for HCT116 cells (Figure S8).

The cellular uptake of Pt-c (as quantified by ICP-MS, Table 1) showed much greater uptake of the Pt(IV) prodrug than OxPt, as is commonly observed in comparisons of Pt(II) and Pt(IV) complex cell uptake, as the Pt(IV) oxidation state affords more cellular accumulation of Pt complexes are often poorly correlated.

The ability of PS-1 to photocatalytically reduce the Pt(IV) prodrug Pt-c into OxPt was confirmed, as shown in Figure 1, with Pt-c reduced into OxPt by 2 mol% PS-1 by illumination (λ = 470 nm, 0.58 mW.cm^{-2}), with 88% conversion observed after 60 min of illumination (Figures S9-S11) with the conversion of Pt-c to OxPt also confirmed by NMR (Figure 1b and Figure S12). To quantify the level of cell death brought on by photoactivation of Pt-c and the dual oxidative damage inflicted by PS-1 SKOV-3-wt and HCT116 cell lines were incubated with PS-1 and Pt-c and irradiated.

**Scheme 2.** Synthesis of the photocatalyst PS-1 and the Pt(IV) prodrugs Pt-a to Pt-g.
Cells that did not undergo irradiation showed little cell death when incubated with either PS-1 or PS-1 with Pt-c (Figure 2b). Whereas when PS-1 was used in conjunction with illumination there was significantly reduced cell viability, due to the generation of \(^{1}O_2\) and other reactive oxygen species. To verify this, the singlet oxygen generation in cells was measured by co-incubation of SOSG and the turn-on of fluorescence tracked over time (Figure S13).

The combination of PS-1 and Pt-c with illumination demonstrated very high levels of light-mediated cytotoxicity in both SKOV-3-wt and HCT116 cell lines. Due to the high uptake of PS-1 and the increased uptake of Pt-c compared to OxPt and the efficacy of the photocatalysed Pt(IV) prodrug activation, it was hypothesised that light-mediated photocatalytic activation of Pt-c may be able to overcome the acquired resistance to OxPt. To explore this, SKOV-3-wt cells were allowed to accrue resistance to oxaliplatin by sub-culturing in incremental doses of OxPt over 3 months (procedure in ESI). The IC\(_{50}\) for OxPt in wild-type SKOV-3 (SKOV-3-wt) cells was 8.8 µM, which increased some 3-fold to 25 µM for the more resistant cells (SKOV-3-OxR). The Pt(IV) prodrug Pt-c again exhibited reduced cytotoxicity compared to its Pt(II) counterpart, OxPt, with IC\(_{50}\) values of 82 vs 25 µM in the SKOV-3-OxR cells.

Photocatalytic activation of Pt-c in SKOV-3-OxR cells elicited substantial cell death, albeit with a slightly diminished cytotoxic effect than in SKOV-3-wt. Harvesting of the cellular DNA was performed 24 h post-photocatalytic activation of Pt-c in SKOV-3-wt and SKOV-3-OxR cells with the Pt content of each analysed by ICP-MS. There was a marked increase in platinated DNA in SKOV-3-wt and SKOV-3-OxR cells when PS-1 and Pt-c were utilised in conjunction with light irradiation compared to controls (Figure S14). Interestingly, there was a larger overall platinated DNA content for SKOV-3-OxR (acquired resistance to oxaliplatin) than with either OxPt or photocatalysed Pt(IV)-Pt(II) conversion compared to SKOV-3-wt i.e. naïve cells towards oxaliplatin. As the photosensitiser was found to primarily localize in the mitochondria (Figure 2a and S15), cellular fractionation (into cytosol, mitochondrial and nuclear fractions) followed by ICP-MS analysis was used to probe the localization of the Pt(IV) prodrug in SKOV-3-wt cells (Figure S16). Pt-c was found mainly in the cytosolic fraction but was distributed throughout the cell, with slightly lower levels in the mitochondria and the nucleus. This ratio of distribution did not appear to be altered by the co-incubation of PS-1.

Finally, to explore the scope of this Pt(IV) prodrug activation system, the ability of two ruthenium-based photosensitisers to reduce three different Pt(IV) species was shown (Figure S17). TLD-1433, a photosensitiser currently under clinical investigation, was capable of reducing two oxaliplatin Pt(IV) species upon illumination of light. This was also shown to be possible with other platinum drugs, such as a Pt(II) cisplatin derivative (Cpt-Ac).

In conclusion, a photocatalytically activated Pt(IV) prodrug to overcome acquired Pt resistance in cells and demonstrated robustness in each of the cell lines used. The catalytic activation of Pt(IV) with concomitant singlet oxygen generation thus allows

### Table 1. Cellular uptake of PS-1 and Pt-c as measured by ICP-MS

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cell Line</th>
<th>Cell Uptake (ng/10(^6) cells)[%]</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PS-1</td>
<td>SKOV-3-wt</td>
<td>275 ± 9 (90 ± 3%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SKOV-3-OxR</td>
<td>191 ± 3 (63 ± 1%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HCT116</td>
<td>190 ± 10 (63 ± 3%)</td>
<td></td>
</tr>
<tr>
<td>Pt-c</td>
<td>SKOV-3-wt</td>
<td>531 ± 20 (14 ± 0.5%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SKOV-3-OxR</td>
<td>384 ± 2 (10 ± 0.04%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HCT116</td>
<td>458 ± 12 (12 ± 0.3%)</td>
<td></td>
</tr>
<tr>
<td>OxPt</td>
<td>SKOV-3-wt</td>
<td>161 ± 11 (1 ± 0.9%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SKOV-3-OxR</td>
<td>150 ± 5 (4 ± 0.4%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HCT116</td>
<td>281 ± 10 (2 ± 0.8%)</td>
<td></td>
</tr>
</tbody>
</table>

[a] Cells were incubated with either PS-1 (1 µM) or Pt-c (20 µM) for 4 h at 37°C (n = 3)
[b] % uptake calculated as proportion of the theoretical maximal uptake.

![Figure 1](image-url)
low dosing of photosensitiser which may help reduce phototoxicity-related side-effects. The composition of the photosensitiser will be further explored in terms of extending the absorption wavelength to more therapeutically applicable ranges through modification of the ligands and further enhancing the cancer-targeting capabilities of photocatalytic compounds that can be used for Pt(IV) prodrug activation.

Acknowledgements

This work was supported by funding from University of Edinburgh and UK Engineering and Physical Sciences Research Council through the Implantable Microsystems for Personalised Anti-Cancer Therapy (IMPACT) programme grant (EPK034510/1). Data used within this publication can be accessed at:

Keywords: platinum • cancer • photocatalysis • prodrugs • anti-tumour agents

Entry for the Table of Contents (Please choose one layout)

Layout 1:

COMMUNICATION

Text for Table of Contents

Layout 2:

COMMUNICATION

Text for Table of Contents

((Insert TOC Graphic here))